Ophthalmology
-
Randomized Controlled Trial
Subconjunctival lidocaine before laser treatment: a randomized trial.
The aim of the study was to determine whether subconjunctival anesthesia is effective at reducing pain associated with laser retinopexy. ⋯ Subconjunctival 2% lidocaine significantly reduces the incidence of pain in patients who receive PRP or PLR.
-
Comparative Study
High-resolution imaging of resolved central serous chorioretinopathy using adaptive optics scanning laser ophthalmoscopy.
To compare pathologic changes in photoreceptors in eyes with resolved central serous chorioretinopathy (CSC) seen on high-resolution images obtained by adaptive optics scanning laser ophthalmoscopy (AO SLO) with visual acuity (VA) and findings on spectral-domain optical coherence tomography (SD OCT). ⋯ Adaptive optics SLO images showed abnormal cone mosaic patterns and reduced cone densities in eyes with resolved CSC, and these abnormalities were associated with VA loss, suggesting that AO SLO is a useful means to detect and measure cone abnormalities associated with VA loss in these eyes.
-
Randomized Controlled Trial Clinical Trial
Vibration-assisted anesthesia in eyelid surgery.
To investigate whether a vibrating device applied in a circular motion to the forehead reduces the pain of local anesthetic injection in upper eyelid surgery. ⋯ The author(s) have no proprietary or commercial interest in any materials discussed in this article.
-
Randomized Controlled Trial Multicenter Study
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
To evaluate the safety and efficacy of dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA) compared with sham in eyes with vision loss due to macular edema (ME) associated with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). ⋯ Dexamethasone intravitreal implant can both reduce the risk of vision loss and improve the speed and incidence of visual improvement in eyes with ME secondary to BRVO or CRVO and may be a useful therapeutic option for eyes with these conditions.